CN112791166B - 一种增强肌肉性能且缓解运动性疲劳的药食同源组合物 - Google Patents
一种增强肌肉性能且缓解运动性疲劳的药食同源组合物 Download PDFInfo
- Publication number
- CN112791166B CN112791166B CN202110095232.XA CN202110095232A CN112791166B CN 112791166 B CN112791166 B CN 112791166B CN 202110095232 A CN202110095232 A CN 202110095232A CN 112791166 B CN112791166 B CN 112791166B
- Authority
- CN
- China
- Prior art keywords
- medicinal
- edible composition
- exercise
- fatigue
- reaches
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 210000003205 muscle Anatomy 0.000 title claims abstract description 27
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 13
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 22
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 22
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 22
- 239000009636 Huang Qi Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 5
- 241000756943 Codonopsis Species 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012674 herbal formulation Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 9
- 229920002527 Glycogen Polymers 0.000 abstract description 7
- 229940096919 glycogen Drugs 0.000 abstract description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 abstract description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 abstract description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 abstract description 4
- 210000003194 forelimb Anatomy 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 4
- 239000004310 lactic acid Substances 0.000 abstract description 3
- 235000014655 lactic acid Nutrition 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 206010016256 fatigue Diseases 0.000 description 25
- 230000000052 comparative effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 8
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 241000007126 Codonopsis pilosula Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000008216 herbs Nutrition 0.000 description 6
- 235000006533 astragalus Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 241000382455 Angelica sinensis Species 0.000 description 4
- 241000045403 Astragalus propinquus Species 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 4
- 229960001948 caffeine Drugs 0.000 description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 4
- 229960003624 creatine Drugs 0.000 description 4
- 239000006046 creatine Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010049565 Muscle fatigue Diseases 0.000 description 3
- 229940107666 astragalus root Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 238000011056 performance test Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 241000125175 Angelica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241001633680 Polygonatum odoratum Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 2
- 244000185386 Thladiantha grosvenorii Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- -1 plasters Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种增强肌肉性能且缓解运动性疲劳的药食同源组合物,属于中药领域。本发明所述的增强肌肉性能且缓解运动性疲劳的药食同源组合物,其组分包括黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁,其中黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁的质量比为1:(1‑2):(0.1‑1.5):(0.1‑2):(0.5‑2):(0.5‑2)。本发明的药食同源组合物进行小鼠实验之后,小鼠的前肢抓力达到190g以上,疲劳转棒仪的运动时间达到95.2s;血清乳酸达到60.1μg/L以下,尿素氮达到102.2μg/L以下,乳酸脱氢酶达到31.8μg/L以上,肌糖原达到4.8μg/L,肝糖原达到9.7μg/L以上。
Description
技术领域
本发明涉及一种增强肌肉性能且缓解运动性疲劳的药食同源组合物,属于中药领域。
背景技术
疲劳是临床上常见的症状,具有复杂的生理病理现象。而运动性疲劳指的是:身体生理机能过程不能继续在特定水平进行和/或不能维持预定的运动强度。运动性疲劳的产生涉及复杂的生理变化,包括氧化损伤、能量消耗、线粒体功能障碍和肌肉收缩能力下降。常导致运动后肌肉延迟性酸痛,其原因主要由于运动时肌肉活动引起局部肌纤维及结缔组织的细微损伤,以及部分肌纤维的痉挛所致。
疲劳是一种正常的反应,对于机体而言,同时也属于保护性机制。然而,如果长期疲劳没有消除,就会发展为过度疲劳,造成运动性疾病与运动性损伤。因此,即时而有效地缓解和消除运动性疲劳至关重要。
根据中国保健协会,我国共批准“抗疲劳”、“缓解体力疲劳”保健食品有1000多种,但是其中具有缓解体力疲劳的功效成分及其配方组合大体相同:咖啡因、肌酸、牛磺酸、赖氨酸、肌醇和B族维生素等。有效的化学药物大多是大脑皮层兴奋剂,包括咖啡因、安非他明、哌醋甲酯等,这些药物在刺激大脑和在相对较短的时间内消除困倦方面作用不大。然而,这些疗法很少能有效地阻止疲劳的进展。此外,一些传统的中枢刺激药物大多是短效的,甚至会使人上瘾,并伴有潜在的副作用。例如,长时间的服用咖啡因可能会出现胃肠不适、便秘、腹泻、恶心呕吐、可以出现精神、和神经系统的症状;而肌酸虽然可以帮助我们的肌肉和神经细胞增长,但是过度的服用会增加身体的水分,增加体重,对于要控制体重者慎用,同时会使肌肉痉挛,增加肾脏的代谢负担,长时间过量服用可引起肾脏功能下降。在这种情况下,进一步研究多靶点、低毒性的新型抗疲劳药物就显得尤为重要。
多种神经系统疾病可以诱发中枢疲劳,主要发生在中枢神经系统、周围神经系统以及自主神经系统。尤其是一些中枢性药物,主要以感觉、听觉、触觉、运动、意识和自主神经功能障碍为靶向,能够治疗肌肉异常、肌肉萎缩、小脑损伤、晕厥等等,然而却不适宜应用于缓解健康、亚健康人群在强体力输出后的疲劳感受。因此,对于体力劳动者而言,开发一款安全、有效的增强肌肉性能且缓解运动性疲劳的药食同源组合物,具有非常广泛的应用前景。
发明内容
为了解决上述至少一个问题,本发明基于“药食同源”的理论,对现有的材料进行了科学配伍,得到了一种中药组合物;其比单一营养品或中药药效更高,并且安全性更好,综合调节糖、脂肪、蛋白质、氨基酸、脂肪酸的能量代谢,达到稳定、缓慢、健康的抗运动性疲劳效果。
本发明的第一个目的是提供一种增强肌肉性能且缓解运动性疲劳的药食同源组合物,其组分包括黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁,其中黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁的质量比为1:(1-2):(0.1-1.5):(0.1-2):(0.5-2):(0.5-2)。
进一步的,所述的药食同源组合物中黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁的质量比为1:(1-1.5):(0.1-1.5):(0.1-1.5):(0.1-1.5):(0.1-1.5);更进一步优选为1:(1-1.5):(0.5-1):(0.5-1):(0.5-1):(0.5-1);
进一步的,所述的药食同源组合物还包括党参,黑玛咖和党参的质量比为1:(0.1-2);进一步优选为1:(0.5-1)。
进一步的,所述的药食同源组合物还包括当归,黑玛咖和当归的质量比为1:(0.1-2);进一步优选为1:(0.5-1)。
进一步的,所述的药食同源组合物还包括甘草,黑玛咖和甘草的质量比为1:(0.5-2)。
进一步的,所述的药食同源组合物还包括罗汉果,黑玛咖和罗汉果的质量比为1:(0.5-2)。
本发明的第二个目的是提供一种制备本发明所述的药食同源组合物的方法,包括如下步骤:
按照质量比称取各原料,之后加入水,加热回流提取,过滤取上清液;将滤渣重复上述提取过程得到上清液,将两次上清液合并,进行浓缩得到药食同源组合物。
进一步的,所述的各原料是经过粉碎之后的。
进一步的,所述的加热回流提取的条件为:在90~100℃下提取1.5~2.5h。
进一步的,所述的各原料和水的质量比为1:6~10。
进一步的,所述浓缩是浓缩至固含量为0.10~0.30g/mL;进一步优选为0.10~0.20g/mL;更进一步优选为0.15~0.20g/mL。
本发明的第三个目的是本发明所述的药食同源组合物在制备缓解运动性疲劳的药物或食品中的应用。
本发明的第四个目的是本发明所述的药食同源组合物在制备增加肌肉性能的药物或食品中的应用。
本发明的第五个目的是提供一种增强肌肉性能且缓解运动性疲劳的中药制剂,其组分包括本发明所述的药食同源组合物。
进一步的,所述的中药制剂包括片剂、胶囊剂、口服液、口含剂、颗粒剂、丸剂、散剂、膏剂、丹剂、混悬剂、粉剂、栓剂、软膏剂、硬膏剂、霜剂、喷雾剂、滴剂、贴剂、滴丸剂。
本发明的第六个目的是一种制备本发明所述的增强肌肉性能且缓解运动性疲劳的中药制剂的方法,包括如下步骤:
在本发明的药食同源组合物中添加辅料,制备得到中药制剂;其中所述的辅料包括露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠、一价碱金属的碳酸盐、醋酸盐、磷酸盐或者水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、淀粉、蔗糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、吐温80、琼脂、碳酸钙、碳酸氢钙、表明活性剂、聚乙二醇、环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁。
本发明的有益效果:
(1)与传统的单靶点药物相比,本发明的药食同源组合物包含多种中草药,并具有协同作用(多化合物-多靶点)。
(2)本发明中药组合物经保健食品功能性检验,具有缓解运动诱导的肌肉疲劳的功能。
(3)本发明旨在采用多种“药食两用”的草药,通过增强肌肉性能,同时补充生命能量,发挥了显着的抗疲劳作用。在调节运动性疲劳方面,玛咖、黄精、黄芪等植物均表现出多种药理活性。
(4)本发明将多种药食两用的植物制备得到具有显著抗肌肉疲劳功效的组合物,并经动物实验评价得以确证。
(5)本发明的药食同源组合物进行小鼠实验之后,小鼠的前肢抓力达到190g以上,疲劳转棒仪的运动时间达到95.2s;血清乳酸达到60.1μg/L以上下,尿素氮达到102.2μg/L以下,乳酸脱氢酶达到31.8μg/L以上,肌糖原达到4.8μg/L,肝糖原达到9.7μg/L以上。
附图说明
图1为实施例1的药食同源组合物对小鼠体重的影响。
图2为实施例1的药食同源组合物对小鼠肌肉组织形态的影响。
具体实施方式
以下对本发明的优选实施例进行说明,应当理解实施例是为了更好地解释本发明,不用于限制本发明。
测试方法:
1、动物实验设计
(1)试验动物:ICR种小鼠,雄性,体重(20±2)g,由上海灵畅实验动物有限公司提供,生产许可证号:SCXK(沪)2018-0003。饲养室温度20-25℃,相对湿度40%-70%。Co60辐照实验鼠生长繁殖饲料由江苏省协同医药生物工程有限责任公司提供,生产许可证号:苏饲证(2019)01008。试验已通过江南大学实验动物中心伦理委员会审核,伦理申请编号:JN.No20200710i0720915。
(2)剂量设计:人体推荐剂量为每日12g中药原料/60kg,折算为小鼠的剂量分别为2g中药原料/kg,相当于人体推荐剂量的10倍;设置咖啡因为阳性对照,剂量为5mg/kg;另设蒸馏水作为空白对照组。
(3)给药途径:灌胃,灌胃容量0.20mL/20g体重。
(4)运动诱导运动性肌肉疲劳模型的建立:最后一次灌胃30min后,将小鼠置于游泳箱中负重游泳。水深不少于30cm,水温25±0.5℃,小鼠尾部负荷5%体重的钢珠。固定小鼠游泳时间为30min,捞出水面,立即解剖取肝脏、肌肉组织,测定运动性疲劳相关的指标。
(5)统计方法:实验结果用SPSS 24.0软件进行方差分析。
(6)实验方法
取小鼠40只,适应性喂养5天后,按体重分层随机分为4组,每组10只。所有动物按剂量设计连续喂养4周,每周称一次体重,根据体重调整给样量。
2、前肢抓力的测试:
用YLS-13A大小鼠抓力测定仪测定小鼠的前肢抓力。将小鼠尾巴夹着抬起来,使其前爪就能抓住力量测量仪上的金属线,然后尾巴与桌子平行,慢慢地向后拉,直到它们失去对金属线的控制。每只小鼠进行三次测试,取平均值进行统计分析。
3、疲劳转棒仪滞留时间的测试:
实验设备采用大小鼠转棒仪(DXP-3,中国医学科学院药物研究所)或转棒仪(LE8200,Panlab,Spain),主要用于测量小鼠的运动协调能力。实验提前一天将小鼠放置在转棒仪上进行常规转棒训练,以实验小鼠能够在15r/min的转速坚持10s以上为完成常规转棒训练。将造模前已进行常规转棒训练的模型置于恒定转速15r/min的转棒仪上,记录小鼠在转棒仪上停留的时间,以转棒持续时间作为测定小鼠运动机能的指标体现。
4、血清乳酸、尿素氮、乳酸脱氢酶、肌糖原和肝糖原含量的测试:
试剂盒法(南京建成)测定血清乳酸、尿素氮、乳酸脱氢酶、肌糖原和肝糖原含量。
5、HE染色
肌肉组织用4%(v/v)多聚甲醛/PBS固定,石蜡包埋,H&E染色,最后在日本东京Olympus光镜下观察(×200)。
实施例1
一种制备药食同源组合物的方法,包括如下步骤:
(1)先将黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁粉碎;
(2)按照重量比为15:20:10:15:10:10将黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁称取得到,之后加入10倍药材重量的纯净水,加热至100℃回流提取2.5h,膜过滤,取上清液;药渣按照上述过程重复提取一次,得到上清液;之后将两次上清液合并,减压浓缩至固形物含量为0.15g/mL。
对照例1
采用和实施例1药食同源组合物用量相同的蒸馏水进行动物实验(空白对照组-不给药、给水、不运动)。
对照例2
采用5mg/kg的咖啡因进行动物实验(阳性对照组-给药、负重运动)。
对照例3
不对小鼠进行任何处理,直接使其运动进行动物实验(运动组-不给药、只给水、负重运动)。
图1为实施例1的药食同源组合物对小鼠体重的影响。从图1可以看出:小鼠体重在灌胃期间,与空白组相比并无显著性差异,说明实施例1的药食同源组合物的剂量在安全范围内。
图2为实施例1的药食同源组合物对小鼠肌肉组织形态的影响。从图2可以看出:在高强度的游泳训练下,运动组小鼠的肌肉在过度运动后,出现肿胀的形态。而实施例1的药食同源组合物组,肌细胞变大,伸缩能力增强,并且在高强度的运动后,未出现肿胀的形态。
实施例2
调整实施例1中黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁的质量比如表1所示,其他和实施例1保持一致,得到药食同源组合物。
将实施例1、2得到的食同源组合物进行性能测试,测试结果如表1:
表1实施例1、2的测试结果
表2实施例1、2的测试结果
对照例4
省略实施例1中的黑玛咖,其他和实施例1保持一致,得到药食同源组合物。
对照例5
调整实施例1中的黑玛咖为人参,其他和实施例1保持一致,得到药食同源组合物。
对照例6
仅保留实施例1中的黑玛咖,省略其他原料,其他和实施例1保持一致,得到药食同源组合物。
对照例1-6的测试结果如下:
表3对照例1-6的测试结果
注:表中对照例4、5、6的中药总质量是相同的。
表4对照例1-6的测试结果
注:表中对照例4、5、6的中药总质量是相同的。
实施例3
一种制备药食同源组合物的方法,包括如下步骤:
(1)先将黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁、党参粉碎;
(2)按照重量比为15:20:10:15:10:10:15将黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁、党参称取得到,之后加入10倍药材重量的纯净水,加热至100℃回流提取2.5h,膜过滤,取上清液;药渣按照上述过程重复提取一次,得到上清液;之后将两次上清液合并,减压浓缩至固形物含量为0.15g/mL。
实施例4
调整实施例3中黑玛咖、黄精、黄芪、陈皮、黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁、党参的质量比如表5所示,其他和实施例3保持一致,得到药食同源组合物。
对照例7
调整实施例3中的中药组合组仅为党参,其他和实施例3保持一致,得到中药组合物。
将实施例3、4和对照例7得到的药食同源组合物进行性能测试,测试结果如下:
表5实施例3、4和对照例7的测试结果
注:表中中药总质量是相同的。
表6实施例3、4和对照例7的测试结果
注:表中中药总质量是相同的。
实施例5
一种制备药食同源组合物的方法,包括如下步骤:
(1)先将黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁、党参、当归粉碎;
(2)按照重量比为15:20:10:15:10:10:15:15将黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁、党参、当归称取得到,之后加入10倍药材重量的纯净水,加热至100℃回流提取2.5h,膜过滤,取上清液;药渣按照上述过程重复提取一次,得到上清液;之后将两次上清液合并,减压浓缩至固形物含量为0.15g/mL。
实施例6
调整实施例5中黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁、党参、当归的质量比如表7所示,其他和实施例5保持一致,得到药食同源组合物。
对照例8
调整实施例5中的中药组合组仅为当归,其他和实施例5保持一致,得到中药组合物。
将实施例5、6和对照例8得到的药食同源组合物进行性能测试,测试结果如下:
表7实施例5、6和对照例8的测试结果
注:表中中药总质量是相同的。
表8实施例5、6和对照例8的测试结果
注:表中中药总质量是相同的。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (6)
1.一种增强肌肉性能且缓解运动性疲劳的药食同源组合物,其特征在于,其组分为黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁、党参、当归,其中黑玛咖、黄精、黄芪、陈皮、玉竹、砂仁、党参、当归的重量比为15:20:10:15:10:10:15:15。
2.一种制备权利要求1所述的药食同源组合物的方法,其特征在于,包括如下步骤:
按照质量比称取各原料,之后加入水,加热回流提取,过滤取上清液;在滤渣中加入水,加热回流提取,过滤得到上清液,将两次上清液合并,进行浓缩得到药食同源组合物。
3.权利要求1所述的药食同源组合物在制备缓解运动性疲劳的药物或食品中的应用。
4.权利要求1所述的药食同源组合物在制备增加肌肉性能的药物或食品中的应用。
5.一种增强肌肉性能且缓解运动性疲劳的中药制剂,其特征在于,其组分包括权利要求1所述的药食同源组合物。
6.一种制备权利要求1所述的增强肌肉性能且缓解运动性疲劳的中药制剂的方法,其特征在于,包括如下步骤:
在权利要求1所述的药食同源组合物中添加辅料,制备得到中药制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110095232.XA CN112791166B (zh) | 2021-01-25 | 2021-01-25 | 一种增强肌肉性能且缓解运动性疲劳的药食同源组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110095232.XA CN112791166B (zh) | 2021-01-25 | 2021-01-25 | 一种增强肌肉性能且缓解运动性疲劳的药食同源组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112791166A CN112791166A (zh) | 2021-05-14 |
CN112791166B true CN112791166B (zh) | 2022-08-09 |
Family
ID=75811548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110095232.XA Active CN112791166B (zh) | 2021-01-25 | 2021-01-25 | 一种增强肌肉性能且缓解运动性疲劳的药食同源组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112791166B (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103877263B (zh) * | 2014-03-27 | 2017-11-10 | 北京三宝利康医药科技有限公司 | 一种红参、玛咖、绿茶提取物(茶氨酸)等复合中药抗疲劳养生制剂 |
-
2021
- 2021-01-25 CN CN202110095232.XA patent/CN112791166B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN112791166A (zh) | 2021-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103877263B (zh) | 一种红参、玛咖、绿茶提取物(茶氨酸)等复合中药抗疲劳养生制剂 | |
CN103285231A (zh) | 一种用于糖尿病辅助治疗的药物组合物及其制法 | |
CN1314422C (zh) | 一种补益气血、温阳健脾十味扶正的药物及其制备方法 | |
CN107997174B (zh) | 一种具有改善睡眠和/或抗抑郁功效的保健组合物和保健食品 | |
CN102783639A (zh) | 一种牛大力保健胶囊及其制备方法 | |
CN102293927B (zh) | 具有抗疲劳和抗氧化功能的复方中药制剂及其制备方法 | |
CN102228595A (zh) | 一种具有抗衰老的汉方能量纯中药提取物 | |
CN117018125B (zh) | 一种用于抗疲劳的药物组合物 | |
CN112675267A (zh) | 一种缓解中枢疲劳的中药组合物及其应用 | |
CN103816278B (zh) | 一种用于降低血糖的组合物及其应用 | |
CN102688471A (zh) | 一种具有抗疲劳作用的复方制剂 | |
CN112439018A (zh) | 具有减肥降脂的组合物及其制备方法和应用 | |
CN112791166B (zh) | 一种增强肌肉性能且缓解运动性疲劳的药食同源组合物 | |
CN101032604A (zh) | 一种治疗血管性头痛的中药制剂 | |
CN114098085B (zh) | 一种具有辅助改善记忆功能的功能性食品组合物及用途 | |
CN102861117A (zh) | 一种中药活性成分组合物及其用途 | |
CN102784230B (zh) | 一种治疗营养性贫血的药物组合物制剂 | |
CN103920140A (zh) | 一种人用降糖减肥降脂复方制剂 | |
CN108904596B (zh) | 一种具有改善记忆力功效的组合物 | |
CN107997170B (zh) | 一种具有降血脂功能的组合物及其制备方法 | |
CN106360716A (zh) | 一种同时改善机体免疫力和睡眠的中药组合物及其制备方法 | |
CN100471488C (zh) | 一种温阳益气、养心安神的中药组合物及其制备方法 | |
CN102949681A (zh) | 一种预防或治疗感冒的组合物及其制备方法 | |
CN111346172B (zh) | 一种提高免疫力的药物组合物 | |
JPH0733676A (ja) | 血糖値降下のための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |